| Autor: |
Halkjær SI; Gastrounit,Medical Division, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark., Refslund Danielsen M; Gastrounit,Medical Division, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark., de Knegt VE; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark., Andersen LO; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark., Stensvold CR; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark., Nielsen HV; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark., Mirsepasi-Lauridsen HC; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.; Department of Science and Environment, Roskilde University, Roskilde, Denmark., Krogfelt KA; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.; Department of Science and Environment, Roskilde University, Roskilde, Denmark., Cortes D; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Petersen AM; Gastrounit,Medical Division, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Microbiology, Copenhagen University Hospital Amager and Hvidovre, Copenhagen, Denmark. |
| Abstrakt: |
Probiotics have been described to influence host health and prevent the risk of obesity by gut microbiome (GM) modulation. In a randomized double-blinded placebo-controlled feasibility study, we investigated whether Vivomixx® multi-strain probiotics administered to 50 women with obesity during pregnancy altered the GM composition and perinatal health outcomes of their infants up to 9 months after birth. The mothers and infants were followed up with four visits after birth: at 3 d, and at 3, 6, and 9 months after delivery. The infants were monitored by anthropometric measurements, fecal sample analysis, and questionnaires regarding health and diet.The study setup after birth was feasible, and the women and infants were willing to participate in additional study visits and collection of fecal samples during the 9-month follow-up. In total, 47 newborns were included for microbiome analysis.Maternal prenatal Vivomixx® administration did not alter infant GM diversity nor differential abundance, and the probiotic strains were not vertically transferred. However, the infant GM exhibited a decreased prevalence of the obesity-associated genera, Collinsella , in the probiotic group and of the metabolic health-associated Akkermansia in the placebo group, indicating that indirect community-scale effects of Vivomixx® on the GM of the mothers could be transferred to the infant.Moreover, 3 d after birth, the GM of the infant was influenced by mode of delivery and antibiotics administered during birth. Vaginally delivered infants had increased diversity and relative abundance of the metabolic health-associated Bifidobacterium and Bacteroides while having a decreased relative abundance of Enterococcus compared with infants delivered by cesarean section. Maternal antibiotic administration during birth resulted in a decreased relative abundance of Bifidobacterium in the GM of the infants. In conclusion, this study observed potential effects on obesity-associated infant GM after maternal probiotic supplementation. |
